Journal of Oncology / 2009 / Article / Tab 1

Review Article

Autoantibodies to Tumor-Associated Antigens in Epithelial Ovarian Carcinoma

Table 1

Frequency of identified circulating AAbs to TAAs in epithelial ovarian carcinoma.

AAb to TAAPositiveTotal%CommentReference

p534217424Association with shorter disease-free survival.[30]
p53188621No prognostic relevance for survival.[22]
p5314365222Summary of 11 studies. Frequency of AAbs: 8.7%–92.3%. Few studies showed association with poor histological differentiation and poor survival.[23]
p53388346Association with higher risk for relapse.[38]
p532111319Correlation with tumor stage and grade. Association with worse survival.[28]
p532811325Serum AAbs had no prognostic relevance for survival. Ascitic AAbs were associated with adverse survival.[24]
p532419313No diagnostic value, even if combined with CA-125. No prognostic relevance for survival.[45]
p532911625Detected exclusively in type II carcinoma.[33]
HOXA7174836Allows no distinction between benign and malignant ovarian tumors.[15]
HOXB7133933Significant difference in the frequency of AAbs between ovarian carcinoma patients and healthy controls. Promising diagnostic potential.[48]
HSP-27173450Promising diagnostic potential. Possible association with improved survival.[49]
HSP-9083225Association with advanced-stage disease. Promising diagnostic potential.[9]
Cathepsin D102540Promising diagnostic potential.[50]
NY-ESO-1/LAGE-1113730No prognostic relevance for survival. Promising diagnostic potential.[11]
MUC130666846Correlation with a more favorable prognosis.[52]
GIPC-161154Promising diagnostic potential.[53]
IL-8NR94NRAnti-IL-8 AAb levels were elevated in ovarian carcinoma patients as compared with those of healthy controls. Promising diagnostic potential.[54]
Ep-CAM225242Potential diagnostic value.[55]
S100A7NR92NRMean AAbs level was significantly higher in ovarian carcinoma patients as compared to that healthy controls. Potential diagnostic value.[2]

NR, not recorded.